Research ExplorerPublicationsProgression-Free Survival and Overall Survival in Patients w...

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab

Standard

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. / Michel, Laura L; Hartkopf, Andreas D; Fasching, Peter A; Kolberg, Hans-Christian; Hadji, Peyman; Tesch, Hans; Häberle, Lothar; Ettl, Johannes; Lüftner, Diana; Wallwiener, Markus; Müller, Volkmar; Beckmann, Matthias W; Belleville, Erik; Volz, Bernhard; Huebner, Hanna; Wimberger, Pauline; Hielscher, Carsten; Mundhenke, Christoph; Kurbacher, Christian; Wuerstlein, Rachel; Untch, Michael; Overkamp, Friedrich; Huober, Jens; Janni, Wolfgang; Taran, Florin-Andrei; Lux, Michael P; Wallwiener, Diethelm; Brucker, Sara Y; Schneeweiss, Andreas; Fehm, Tanja N.

In: CANCERS, Vol. 12, No. 10, 17.10.2020.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Michel, LL, Hartkopf, AD, Fasching, PA, Kolberg, H-C, Hadji, P, Tesch, H, Häberle, L, Ettl, J, Lüftner, D, Wallwiener, M, Müller, V, Beckmann, MW, Belleville, E, Volz, B, Huebner, H, Wimberger, P, Hielscher, C, Mundhenke, C, Kurbacher, C, Wuerstlein, R, Untch, M, Overkamp, F, Huober, J, Janni, W, Taran, F-A, Lux, MP, Wallwiener, D, Brucker, SY, Schneeweiss, A & Fehm, TN 2020, 'Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab', CANCERS, vol. 12, no. 10. https://doi.org/10.3390/cancers12103021

APA

Michel, L. L., Hartkopf, A. D., Fasching, P. A., Kolberg, H-C., Hadji, P., Tesch, H., Häberle, L., Ettl, J., Lüftner, D., Wallwiener, M., Müller, V., Beckmann, M. W., Belleville, E., Volz, B., Huebner, H., Wimberger, P., Hielscher, C., Mundhenke, C., Kurbacher, C., ... Fehm, T. N. (2020). Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. CANCERS, 12(10). https://doi.org/10.3390/cancers12103021

Vancouver

Michel LL, Hartkopf AD, Fasching PA, Kolberg H-C, Hadji P, Tesch H et al. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. CANCERS. 2020 Oct 17;12(10). https://doi.org/10.3390/cancers12103021

Bibtex

@article{ad2bb7c7462a441cb41b4f1e9a43d4c9,
title = "Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab",
abstract = "The approval of trastuzumab emtansine (T-DM1) was conducted without pertuzumab as previous therapy. Efficacy data on T-DM1 following pertuzumab treatment are therefore limited. This study explores this issue in a real-world setting. Within the prospective PRAEGNANT (Prospective Academic Translational Research Network for the Optimization of the Oncological Health Care Quality in the Advanced Setting) metastatic breast cancer registry (NCT02338167), patients in all therapy lines receiving any kind of treatment were eligible for inclusion. This report describes patient characteristics and progression-free survival (PFS) in human epidermal growth factor receptor 2 (HER2)-positive patients receiving T-DM1 after pertuzumab treatment. Seventy-six patients were identified, 39 of whom received T-DM1 as second-line therapy, 25 as third-line, and 12 as fourth-line therapy or higher. Pertuzumab was mostly administered as a first-line treatment (n = 61; 80.3%). The median PFS in all patients was 3.5 months (95% CI: 2.8-7.8); in second-line treatment, 7.7 months (95% CI: 2.8-11.0); in third-line, 3.4 months (95% CI: 2.3-not reached (NR)); and in fourth-line therapy or higher, 2.7 months (95% CI: 1.2-NR). T-DM1 was mainly administered second-line after pertuzumab, but also in more heavily pretreated patients. The PFS in higher therapy lines appears to be shorter than in second-line.",
author = "Michel, {Laura L} and Hartkopf, {Andreas D} and Fasching, {Peter A} and Hans-Christian Kolberg and Peyman Hadji and Hans Tesch and Lothar H{\"a}berle and Johannes Ettl and Diana L{\"u}ftner and Markus Wallwiener and Volkmar M{\"u}ller and Beckmann, {Matthias W} and Erik Belleville and Bernhard Volz and Hanna Huebner and Pauline Wimberger and Carsten Hielscher and Christoph Mundhenke and Christian Kurbacher and Rachel Wuerstlein and Michael Untch and Friedrich Overkamp and Jens Huober and Wolfgang Janni and Florin-Andrei Taran and Lux, {Michael P} and Diethelm Wallwiener and Brucker, {Sara Y} and Andreas Schneeweiss and Fehm, {Tanja N}",
year = "2020",
month = oct,
day = "17",
doi = "10.3390/cancers12103021",
language = "English",
volume = "12",
journal = "CANCERS",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "10",

}

RIS

TY - JOUR

T1 - Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab

AU - Michel, Laura L

AU - Hartkopf, Andreas D

AU - Fasching, Peter A

AU - Kolberg, Hans-Christian

AU - Hadji, Peyman

AU - Tesch, Hans

AU - Häberle, Lothar

AU - Ettl, Johannes

AU - Lüftner, Diana

AU - Wallwiener, Markus

AU - Müller, Volkmar

AU - Beckmann, Matthias W

AU - Belleville, Erik

AU - Volz, Bernhard

AU - Huebner, Hanna

AU - Wimberger, Pauline

AU - Hielscher, Carsten

AU - Mundhenke, Christoph

AU - Kurbacher, Christian

AU - Wuerstlein, Rachel

AU - Untch, Michael

AU - Overkamp, Friedrich

AU - Huober, Jens

AU - Janni, Wolfgang

AU - Taran, Florin-Andrei

AU - Lux, Michael P

AU - Wallwiener, Diethelm

AU - Brucker, Sara Y

AU - Schneeweiss, Andreas

AU - Fehm, Tanja N

PY - 2020/10/17

Y1 - 2020/10/17

N2 - The approval of trastuzumab emtansine (T-DM1) was conducted without pertuzumab as previous therapy. Efficacy data on T-DM1 following pertuzumab treatment are therefore limited. This study explores this issue in a real-world setting. Within the prospective PRAEGNANT (Prospective Academic Translational Research Network for the Optimization of the Oncological Health Care Quality in the Advanced Setting) metastatic breast cancer registry (NCT02338167), patients in all therapy lines receiving any kind of treatment were eligible for inclusion. This report describes patient characteristics and progression-free survival (PFS) in human epidermal growth factor receptor 2 (HER2)-positive patients receiving T-DM1 after pertuzumab treatment. Seventy-six patients were identified, 39 of whom received T-DM1 as second-line therapy, 25 as third-line, and 12 as fourth-line therapy or higher. Pertuzumab was mostly administered as a first-line treatment (n = 61; 80.3%). The median PFS in all patients was 3.5 months (95% CI: 2.8-7.8); in second-line treatment, 7.7 months (95% CI: 2.8-11.0); in third-line, 3.4 months (95% CI: 2.3-not reached (NR)); and in fourth-line therapy or higher, 2.7 months (95% CI: 1.2-NR). T-DM1 was mainly administered second-line after pertuzumab, but also in more heavily pretreated patients. The PFS in higher therapy lines appears to be shorter than in second-line.

AB - The approval of trastuzumab emtansine (T-DM1) was conducted without pertuzumab as previous therapy. Efficacy data on T-DM1 following pertuzumab treatment are therefore limited. This study explores this issue in a real-world setting. Within the prospective PRAEGNANT (Prospective Academic Translational Research Network for the Optimization of the Oncological Health Care Quality in the Advanced Setting) metastatic breast cancer registry (NCT02338167), patients in all therapy lines receiving any kind of treatment were eligible for inclusion. This report describes patient characteristics and progression-free survival (PFS) in human epidermal growth factor receptor 2 (HER2)-positive patients receiving T-DM1 after pertuzumab treatment. Seventy-six patients were identified, 39 of whom received T-DM1 as second-line therapy, 25 as third-line, and 12 as fourth-line therapy or higher. Pertuzumab was mostly administered as a first-line treatment (n = 61; 80.3%). The median PFS in all patients was 3.5 months (95% CI: 2.8-7.8); in second-line treatment, 7.7 months (95% CI: 2.8-11.0); in third-line, 3.4 months (95% CI: 2.3-not reached (NR)); and in fourth-line therapy or higher, 2.7 months (95% CI: 1.2-NR). T-DM1 was mainly administered second-line after pertuzumab, but also in more heavily pretreated patients. The PFS in higher therapy lines appears to be shorter than in second-line.

U2 - 10.3390/cancers12103021

DO - 10.3390/cancers12103021

M3 - SCORING: Journal article

C2 - 33080911

VL - 12

JO - CANCERS

JF - CANCERS

SN - 2072-6694

IS - 10

ER -